Italia Markets closed

Guerbet SA (0ELV.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
37,10+0,10 (+0,27%)
Alla chiusura: 04:09PM BST
Schermo intero
Chiusura precedente37,00
Aperto36,70
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno36,70 - 37,10
Intervallo di 52 settimane15,70 - 37,10
Volume273
Media Volume1.642
Capitalizzazione463,056M
Beta (5 anni mensile)0,71
Rapporto PE (ttm)14,38
EPS (ttm)2,58
Prossima data utili18 apr 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Guerbet: CHMP positive opinion

    The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ (Gadopiclenol)with the indication of use for magnetic resonance imaging with contrast enhancement in adults and children aged 2 years and over If approved by the European Commission, Elucirem™ (Gadopiclenol) will mark a step forward in innovation in MRI contrast media, thus answering to the Health authorities recommendation and concerns of patients and radiologists in Europe. An MRI exam with Elucirem™ r

  • GlobeNewswire

    Guerbet: 2023 half-year results

    Half-year results 2023 Acceleration of activity Half-year revenue: €378.6 million, up 2.8% at CER1Strong acceleration of activity in the second quarter, up 6.7% at CER Profitability in line with expectations EBITDA for the first half-year: €45.9 million, compared to €50.5 million one year earlierThe restated EBITDA margin2 amounted to 12.7% of revenue 2023 objectives confirmed Revenue: expected growth of more than 5% on a like-for-like basis and at CERExpected restated EBITDA margin2 around 11%,

  • GlobeNewswire

    Guerbet: First-half 2023 revenue

    First-half 2023 revenue Acceleration of activity Half-year revenue: €378.6 million, up +2.8% at CER1, with a strong acceleration of activity in Q2, at +6.7%Very dynamic sales in Asia (+16.6% in H1 at CER) and EMEA (+7.8%), but down in the Americas (-15.3%), as expected Financial objectives confirmed 2023 revenue growth of more than 5% on a like-for-like basis and at CERRestated EBITDA margin rate2: around 11% in 2023, before a return in 2024 to a higher level than in 2021 (14.4%) Group debt refi